A Drug May Help People on GLP-1 Meds Preserve Muscle

Why It Matters

If muscle loss can be mitigated, GLP‑1 therapies may become safer for broader populations, including older adults at risk of sarcopenia.

Key Takeaways

• Apitegromab cut lean‑mass loss by 50% in tirzepatide trial
• Muscle preservation linked to slight improvements in grip and leg strength
• Study involved 102 overweight/obese participants over 24 weeks
• Drug remains investigational, delivered by monthly IV infusion

Pulse Analysis

GLP‑1 receptor agonists such as tirzepatide have reshaped obesity treatment, delivering rapid, clinically meaningful weight loss. However, the rapid reduction often includes a proportion of lean tissue—estimated at 25‑40 percent—raising concerns among clinicians about potential impacts on strength, metabolism, and long‑term health. The underlying biology involves myostatin, a hormone that limits muscle growth; blocking this pathway has been a target for muscular dystrophy therapies, suggesting a logical crossover for weight‑loss patients who risk muscle depletion.

In the recent Nature Medicine proof‑of‑concept trial, researchers paired tirzepatide with apitegromab, a monoclonal antibody that inhibits myostatin. Over 24 weeks, 102 participants with BMI in the overweight or obese range received weekly tirzepatide injections; half also received monthly apitegromab infusions. Both arms lost comparable total weight, but the combination group lost roughly half the lean mass of the tirzepatide‑only group. Functional tests showed modest gains in grip strength and leg endurance, hinting that preserved muscle may translate to better physical performance, though the sample size was limited.

The findings open a potential pathway for personalized obesity pharmacotherapy, especially for populations where muscle loss is clinically undesirable—elderly patients, athletes, or individuals with pre‑existing sarcopenia. Commercially, a successful muscle‑preserving adjunct could differentiate GLP‑1 products in a crowded market and extend their use beyond pure weight loss. Yet regulatory hurdles remain; apitegromab is still investigational and requires extensive safety data before FDA approval. Future large‑scale studies will need to confirm functional benefits, assess long‑term outcomes, and evaluate cost‑effectiveness before clinicians can adopt a combined regimen as standard care.